A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Aflibercept in Combination With FOLFIRI Administrated Every 2 Weeks in Chinese Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sanofi
- 19 Jan 2017 Results published in the Investigational New Drugs
- 06 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Mar 2014 Planned end date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.